Bioventus (NYSE:BVS) Updates FY 2025 Earnings Guidance

Key Points

• Bioventus has updated its FY 2025 earnings guidance, projecting EPS of 0.640-0.680, lower than the consensus estimate of 0.707, and revenue guidance of $560.0 million-$570.0 million compared to a consensus of $565.2 million.
• The company’s stock traded down 5.8% to $6.87 following the guidance update, with a market cap of $563.92 million and a price-to-earnings ratio of -11.25.
• Institutional investors hold 62.94% of Bioventus stock, with a recent stake increase by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. of 7.2% in the first quarter.

Bioventus (NYSE:BVS - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus EPS estimate of 0.707. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $565.2 million.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Bioventus in a research report on Monday, July 7th. They issued an "overweight" rating and a $12.00 price target for the company. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the company a "buy" rating in a research note on Wednesday, May 7th.

Bioventus Trading Up 0.1%

BVS stock traded up $0.01 during midday trading on Monday, reaching $6.93. The company's stock had a trading volume of 381,777 shares, compared to its average volume of 395,839. The business's 50-day simple moving average is $6.68 and its 200-day simple moving average is $7.97. The stock has a market cap of $569.26 million, a PE ratio of -11.36 and a beta of 0.83. Bioventus has a 52 week low of $5.81 and a 52 week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Hedge Funds Weigh In On Bioventus

An institutional investor recently raised its position in Bioventus stock. Goldman Sachs Group Inc. lifted its position in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 19.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 162,412 shares of the company's stock after acquiring an additional 26,103 shares during the period. Goldman Sachs Group Inc. owned approximately 0.20% of Bioventus worth $1,486,000 as of its most recent filing with the Securities and Exchange Commission. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.